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Background & Aims—Isoniazid is a leading cause of liver injury but it is not clear how many 
cases are reported or how many clinicians adhere to American Thoracic Society (ATS) guidelines. 
We collected data on cases of isoniazid hepatotoxicity and assessed adherence to ATS guidelines 
and reports to the Center for Disease Control’s (CDC) isoniazid severe adverse events program.
Methods—We analyzed Drug Induced Liver Injury Network (DILIN) cases considered definite, 
highly likely, or probable for isoniazid injury from 2004 through 2013. We assessed the delays in 
isoniazid discontinuance according to ATS criteria and hepatotoxicity severity by Severity Index 
Score. We checked reporting to the CDC by matching cases based on age, latency, indication, 
reporting period, and comorbidities.
Results—Isoniazid was the second most commonly reported agent in the DILIN, with 69 cases; 
60 met inclusion criteria. The median age of cases was 49 y (range 4–68 y), 70% were female, 
97% had latent tuberculosis, and 62% were hospitalized. Patients took a median of 9 days to stop 
taking isoniazid (range 0–99 days). Thirty-three of cases (55%) continued taking isoniazid for 
more than 7 days after the ATS stopping criteria were met. Twenty-four cases (40%) continued 
isoniazid for more than 14 days after meeting stopping criteria. A delay in stopping was associated 
with more severe injury (P<.05). Of 13 patients who died or underwent liver transplantation, 9 
(70%) continued taking isoniazid for >7 days after meeting stopping criteria. Only 1/25 cases of 
isoniazid hepatotoxicity eligible for reporting to the CDC were reported.
Conclusions—Poor adherence to ATS guidelines is common in cases of hepatotoxicity and is 
associated with more severe outcomes including hospitalization, death, and liver transplantation. 
Isoniazid continues to be a leading cause of DILI in the US, and its hepatotoxicity is significantly 
under-reported.
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INTRODUCTION
Hepatotoxicity from isoniazid (INH) was reported shortly after the drug’s introduction in the 
1950’s.1–4 Elevation of serum ALT greater than 5 times ULN occurs in 3–5% of patients, 
and severe injury in less than 1%.5 The American Thoracic Society (ATS) recommends 
monitoring serum alanine aminotransferase (ALT) only in patients with pre-existing liver 
disorders or other risks for hepatotoxicity.6 Otherwise patients are instructed to stop their 
INH if they develop nausea, abdominal pain, jaundice or unexplained fatigue.6 If the serum 
ALT level is greater than 3 times upper limit of normal (ULN), INH should be stopped. If 
there are no symptoms, INH should be stopped only if the ALT is greater than 5 times ULN.
Though studies suggest a low incidence of severe hepatotoxicity7,8 under reporting is 
suspected. The Drug Induced Liver Injury Network (DILIN) is a multi-center study funded 
by the NIH to create a large registry of well-characterized cases of idiosyncratic DILI for 
clinical and translational studies. Amongst INH hepatotoxicity cases, we noted poor 
adherence to stopping guidelines with substantial delays in drug discontinuance. We 
quantified these delays and tested for association with severity of hepatotoxicity. The DILIN 
was initiated in 2004, the same year the CDC started a national project to capture severe 
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adverse events (SAE) associated with INH given for latent TB.9 Therefore, we assessed 
completeness of reporting to the CDC by examining whether our cases appeared in the CDC 
report.
MATERIALS AND METHODS
Design
The design of the DILIN prospective and retrospective studies have been described.10 
Patients suspected of having idiosyncratic drug induced liver injury (DILI) are enrolled 
within 6 months of liver injury for the prospective study. For the retrospective study, 
patients can be enrolled up to 10 years after the event for 7 agents one of which is isoniazid. 
Inclusion criteria include serum aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) greater than 5 times upper limit of normal (ULN) (or pretreatment 
baseline if abnormal) on 2 consecutive occasions, or alkaline phosphatase (AP) levels 
greater than 2 times ULN (or pretreatment baseline if abnormal) on 2 consecutive occasions. 
Patients with serum bilirubin greater than 2.5 mg/dL or INR greater than 1.5, and any 
elevation in AST, ALT, or AP, are also eligible. Subjects are followed for at least 6 months. 
Complete history, physical, past medical history, laboratory values, and imaging data are 
obtained. Severity of DILI is assessed semi-quantitatively using the DILIN Severity Index 
Score (SIS) (Table 1).
Diagnosis of DILI (causality assessment)
DILIN uses a consensus expert opinion method of causality assessment previously 
described.10 Each case is evaluated by 3 DILIN hepatologists. Each independently assigns a 
causality score representing percent likelihood of attribution (1 = definite or > 95% 
likelihood, 2 = highly likely or 75–95%, 3 = probable or 50–74%, 4 = possible or 25–49%, 
and 5 = unlikely or < 25%). Consensus is reached by e-mail and conference call.
Participants
We identified INH cases enrolled by April 15, 2013. Analysis was limited to cases that were 
probable, highly likely or definite INH hepatotoxicity. Probable cases were included only if 
no other agent was implicated.
Data and Outcomes
Demographic, history and laboratory data were analyzed with special attention to onset of 
symptoms, onset of elevated liver enzymes, and drug stop date. Patient data included race, 
ethnicity, and education level. Primary language, country of birth, English speaking ability, 
literacy and recollection of instructions given were not recorded. The pattern of injury was 
categorized as hepatocellular, cholestatic, or mixed based upon the R-value: R-value = 
(serum ALT value/serum ALT ULN) ÷ (serum AP value/serum AP ULN). R-values greater 
than 5 are considered hepatocellular, less than 2 cholestatic, and 2–5 mixed. Standard 
descriptive statistics were used. Correlations between Severity Index Score, delay in 
stopping INH and clinical variables were performed using Chi-square, Fisher’s Exact, 
Median test, Mann-Whitney and Spearman’s rho correlation coefficient where appropriate.
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Matching cases to the CDC SAE reporting program
The CDC reporting program published findings from 2004 through 2008.9 Therefore, we 
examined the 25 of our cases that were treated for latent TB and had occurrence of 
hepatotoxity from January 1, 2004 through December 31, 2008. We looked for these 25 
cases in the CDC report by matching age (+/− 3 years), comorbidities, latency to injury (+/− 
1 month), delay in stopping (+/−1 week), and outcome.
Role of Funding Source and Institutional Board Review (IRB)
The DILIN Network is structured as a U01 cooperative agreement with funds provided by 
the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Separate 
IRB approvals were maintained at each DILIN center throughout the time period of this 
study.
RESULTS
Subjects
Among 1091 patients in the DILIN by April 15, 2013, INH was listed as a potential cause in 
69 (6.5%), and 60 of these met our current study inclusion criteria. INH was second only to 
amoxicillin-clavulanate as a causative medication. Of these 60 patients, 42 (70%) were 
women (Table 2). The median age was 49 years (range 4–68). Almost all (97%) were 
prescribed INH for latent TB infection. Four patients were under 18 (range 4–17). All were 
given INH for latent infection. Jaundice, nausea and abdominal pain were frequent 
presenting symptoms. Seven (12%) had chronic hepatitis C, but there were no other liver 
disorders identified.
Diagnostic/Causality Scoring
Nine patients were excluded because of low likelihood of INH hepatotoxicity. In two, INH 
was the only agent implicated, but each patient scored only a 4 (possible). The other 7 
involved other medications along with INH and the INH scored only a 3 (probable) or 4 
(possible). Of the 60 meeting inclusion criteria, 18 had enrolled into retrospective study and 
42 into the prospective study. Twenty-nine (48%) were considered definite (score 1) and 23 
(38%) highly likely (score 2), and 8 (13%) probable (score 3) with only INH involved. In 5 
patients, six other agents (rifampin, anakinra, Hydroxycut®, fenofibrate, topiramate, 
leflunomide) were considered as potentially causal. All these competing agents were 
considered less likely than INH to be causal, and INH scored either a 2 (highly likely) or 1 
(definite) in each of these multi-drug cases.
Retrospective vs. Prospective Cases
There were no statistically significant differences between the 18 retrospectively and the 42 
prospectively enrolled patients in terms of age, gender, peak liver enzymes, peak bilirubin, 
or time from INH start to symptoms. Retrospective patients tended to be more severe with 6 
(33%) undergoing liver transplantation and/or dying compared to only 7 (17%) for the 
prospective patients, p = 0.09.
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Pattern of Injury
Patterns of liver injury at presentation were predominantly hepatocellular with 55 (92%) of 
patients having an R-value > 5. Four patients (7%) had a mixed pattern (R-value 2–5). No 
patients had a cholestatic pattern (R-value < 2). One patient did not have an alkaline 
phosphatase drawn at presentation so no R-value could be calculated, but the ALT was 2232 
U/L. The mean days from INH initiation to elevated ALT was 97 (standard deviation [S.D.] 
64). Mean days to an ALT level 5 times the ULN was 103 (S.D. 59). The mean time from 
DILI onset to peak ALT was short (6.6 days, S.D. 9). Decline in ALT to 50% or less of peak 
value took a mean of 38 days (S.D. 66.7) but the data were skewed with median being only 
13 days. It took a mean of 200 days (S.D. 348) for the ALT to fall from peak to normal.
Severity of Injury
Distribution of DILIN Severity Index Scores is shown in Figure 1. Twelve patients required 
liver transplant and one of these ultimately died. Another died without transplant. Thirty-
seven patients (62%) required hospitalization and 14 (23%) developed encephalopathy. 
Mean peak ALT, bilirubin and INR were 1385 IU/L (S.D. 864), 12.7 mg/dL (S.D. 11.6) and 
2.6 (S.D. 4.3) respectively.
Delay in Discontinuance of INH and Severity of Injury
Median delay between meeting ATS stopping criteria and discontinuance was 9 days, with 
skewing toward longer delays (mean 17.9, S.D. 23.8, range 0 – 99 days). Only 27 (45%) 
patients stopped within 7 days of meeting criteria, and 24 (40%) kept taking their INH for 
more than 14 days. (Figure 2) Nine patients (15%) took the INH for > 28 days beyond 
reaching stopping criteria, and 6 of these kept taking the INH for >60 days. The delays 
primarily occurred in patients who developed symptoms but did not hold the INH until 
much later when the patient sought medical attention. In contrast, the median delay after 
elevated ALT criteria being met was 0 days with a mean of 3.2 days (S.D. 13.2, range 0–99 
days). However the delays even after ALT criteria being documented were also skewed with 
some remarkable continuances of INH for 8, 10, 18, 20 and 99 days. Based on symptoms 
alone, the median and mean delays were 14 and 20 days.
Longer delays in stopping INH correlated with higher DILIN Severity Index Score (SIS) (p 
= 0.05, Spearman’s rho). One remarkable patient developed hepatic tolerance where serum 
ALT reached >1000 U/L but the provider allowed the INH to continue for more than 3 
months. The ALT fell while still on INH and there was only mild injury (SIS 1). If this 
patient is excluded as a rare outlier, correlation between delay and SIS was even stronger (p 
= 0.02). Of the 27 patients who stopped INH within 7 days of meeting stopping criteria, 6 
(22%) had a severe or fatal reaction (SIS 4 or 5), and of the 33 who continued the INH for 
more than a week, 16 (49%) had a severe or fatal course. Conversely, 5 (36%) of the 14 
patients with mild injury (SIS 1) compared to 16 (73%) of the 22 with severe or fatal injury 
(SIS = 4–5) continued the INH for more than a week after meeting stopping criteria. Higher 
BMI also correlated with increased SIS (p=0.02). Older age, race, ethnicity, education level 
and gender did not correlate with severity.
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Chronic hepatitis C (CHC) was present in 7 (12%) (Table 2). These cases tended to have 
fewer severe or fatal DILIs compared to non-CHC cases, but the difference did not reach 
statistical significance [1 of 7 vs. 19 of 53, p = 0.20]. However, the median delay in stopping 
INH was statistically shorter for those with CHC compared to non-CHC cases (0 vs. 12 
days, p = 0.03). Only 2 of the CHC cases stopped based on elevated liver enzymes alone, 
while 2 stopped when both symptoms and elevated enzymes were discovered on the same 
day and 3 stopped for only symptoms with elevated enzymes found several days later. The 
one fatal case with CHC had cirrhosis and hepatocellular carcinoma already.
There was no correlation between delay and age, gender, race, ethnicity, education level, or 
indication for INH therapy (latent versus active TB infection). Of the 4 children, a 17 year 
old delayed stopping her INH by 15 days and required transplant. The other 3 had mild (SIS 
=1) or moderate (SIS = 2) injuries with delays in stopping of 0 to 29 days.
Matching Cases in the CDC Reporting Program
The CDC report obtained clinical details on only 10 of their 17 cases reported from 2004 
through 2008.9 Of the 25 DILIN cases that should have been reported to the CDC program 
during this period, only 1 appeared to be among the 10 CDC cases with detailed clinical 
history based on matched age, duration of therapy, delay in stopping INH, comorbidities 
(depression) and outcome (transplanted). For this one case, the matching of data was nearly 
perfect. The other 9 CDC cases differed widely in age, outcome, latency and/or 
comorbidities from the other 24 DILIN cases, making them very unlikely to be any of our 
cases.
DISCUSSION
Approximately 300,000 people in the U.S. are treated for latent TB each year and another 
10,000 are treated for active infection.11,12 American Thoracic Society (ATS) guidelines to 
prevent liver injury rely heavily on patient self-identification of symptoms.6 Patients are 
instructed to stop taking INH for symptoms of hepatitis and seek medical attention. Our data 
suggest that poor adherence to these guidelines is common in patients with INH 
hepatotoxicity and leads to more severe injury. Of those that died or needed transplantation, 
70% had continued the INH for a week or more after meeting stopping criteria. Therefore 
many of the severe injuries may have been avoided. Our data also raises concerns for under 
reporting and under estimation of risk.
The prolonged use of INH in our 60 patients was substantial with over half taking the INH 
more than 1 week beyond stopping criteria and 40% more than 2 weeks (Figure 2). Almost 
all (97%) of the patients in our study were treated for latent TB and one fifth required liver 
transplantation and/or died. The vast majority of delays occurred because patients ignored 
symptoms (even jaundice), but occasionally providers also failed to recognize symptoms or 
elevated transaminases. Four patients continued INH for over a week after serum ALT 
exceeded stopping levels. Delay correlated with injury severity including need for 
hospitalization and fatality.
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Surveillance by self-identification of symptoms is appealing because patients are 
empowered to stop the INH without waiting to see a provider. However inadequate patient 
instruction or comprehension may be undermining effectiveness for a small but important 
subset of patients. Such delay in stopping INH has been reported in two smaller case series 
over the last 20 years.9,13 Clear stopping criteria were published in 2006,6 but our data 
suggest delays continue to cause severe hepatotoxicity. There is no lower age limit for latent 
TB treatment.14 Thus children deserve special consideration because they may not identify 
symptoms as readily as adults. One child in our study needed transplantation after 
continuing INH for 15 days beyond stopping criteria.
The 7 patients with concurrent chronic hepatitis C (CHC) tended to have less severe injury 
and significantly less delay in stopping. Adherence to guidelines which includes monitoring 
of liver biochemistries seems better in those with chronic liver disease. In fact, the median 
delay in discontinuance for the CHC patients was 0 days. DILI was detected by symptoms 
as often as by lab abnormalities, suggesting that these patients were more vigilant of their 
symptoms.
Treating latent TB has been a marked success.8,15 Deaths due to TB have fallen since 1988 
to an all-time low of 0.2/100,000 in 2009.16 However, INH remains the most common cause 
of idiosyncratic DILI leading to liver transplantation nationwide.17 It is the second most 
common agent implicated in the DILIN despite under reporting. In 2004, the CDC began a 
national reporting project of SAE’s associated with latent TB therapy.9 From 2004 through 
2008, only 17 cases of INH hepatotoxicity were reported. Twenty-five of our 60 case should 
have been recorded with the CDC, but only 1 was reported. The CDC report had clinical 
details on only 10 of 17 cases. Even if all 7 remaining CDC cases lacking clinical details 
were in the DILIN cohort, then, at most, 8 of 25 (32%) of our cases may have been reported. 
Moreover, the 8 DILIN sites represent only 9% of U.S. liver transplant centers. Non-
transplant centers probably care for many more unreported INH hepatotoxicity patients that 
do not need or qualify for transplantation. Thus under-reporting of INH hepatotoxicity is 
assuredly substantial. DILI, in general, may be more common than previously estimated 
according to pharmacoepidemiologic results from Iceland where data on prescriptions and 
hepatotoxicity are robust.18 A meaningful incidence for INH was not available in this study 
because INH is uncommonly prescribed in Iceland.
Our study is subject to recall bias by patients reporting symptom start dates. However, this 
bias would tend to underestimate delay in stopping because of regrets or embarrassment 
about ignoring symptoms. Reporting bias toward more severe cases is another limitation. 
We do not capture mild injury cases where guidelines were followed. Therefore, the 
minority of significant hepatotoxicity cases is small compared to the large number who are 
safely treated. However, these cases of hepatotoxicity must not be summarily dismissed as 
an unavoidable cost to treating the overall latent TB population either. Many of the life 
threatening injures in our registry may have been easily prevented with better provider-to-
patient education.
We found no correlation between delay in stopping and age, gender, race, ethnicity or 
education level. However, we did not collect data on health care providers, quality of patient 
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instruction, patient primary language, health care literacy, or cultural barriers. These data are 
critical to assessing compliance especially in the latent TB population. The clinician must 
strike a difficult balance between convincing asymptomatic patients to take the INH, while 
also warning them of hepatotoxicity risk. A complete behavioral model addressing 
compliance is beyond the scope of our data, but the DILIN draws attention to this group of 
harmed patients who otherwise may continue to be overlooked.
For now, there are measures to improve compliance that should be considered. There are no 
data on directly observed therapy (DOT) and hepatotoxicity avoidance, but piggybacking a 
review of systems onto DOT might be cost effective. DOT of INH for 3–9 months is already 
a recommended option for latent TB.12 Unfortunately we did not record DOT information. 
Finger-stick technology for point-of-care ALT measurement could also be effective.19 Over 
half the U.S. population own smartphones, so automated texting to remind patients of 
stopping rules may be feasible.20,21 Such interventions could result in substantial cost 
savings by avoiding hospitalizations, intensive care, and transplants.
Our study also highlights the limitations symptoms and ALT monitoring. Of the 13 fatal or 
transplanted patients, 4 (31%) stopped INH quickly (within 7 days of meeting criteria). 
Conversely, two patients continued INH for more than 3 weeks yet had mild injury. One had 
remarkable adaptation with the ALT peaking over 1000 U/L only to fall despite continuing 
the INH. Such adaptation to INH injury has been described, but is quite rare with such 
severe ALT elevation.22–25 In 1976, Mitchell and colleagues concluded that ALT alone 
could not predict serious liver injury with complete accuracy.25 A better diagnostic test is 
overdue.
Current monitoring guidelines are successful for the vast majority of patients treated for 
latent TB and there is no arguing the public health success of treatment programs. However 
our registry draws attention to an important minority of latent TB patients who are harmed 
by suboptimal adherence and prolonged drug exposure. Underreporting is common, so the 
true incidence of such cases is significantly larger than currently captured. Failures to avoid 
such severe iatrogenic injury are particularly difficult to countenance when the latent TB 
patient was otherwise healthy prior to therapy and simply needed better education, 
reminders or monitoring.
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Figure 1. 
Distribution of 60 INH hepatotoxicity patients by Severity Index Scores (SIS). (SIS 1 = 
Mild, SIS 2 = Moderate, SIS 3 = Moderate-Hospitalized, SIS 4 = Severe, SIS 5 = Fatal).
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Figure 2. 
Distribution of delay in stopping INH after stopping rules of the American Thoracic Society 
guidelines had been met. (n = 60)
Hayashi et al. Page 12
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2015 November 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Hayashi et al. Page 13
Table 1
DILIN Severity Index Score
1 Mild Patient has elevations in serum aminotransferase or alkaline phosphatase levels but total bilirubin is < 2.5 
mg/dL and there is no coagulopathy (INR <1.5).
2 Moderate Patient has elevations in serum aminotransferase or alkaline phosphatase levels and total bilirubin is ≥ 2.5 
mg/dL or there is coagulopathy (INR ≥1.5) without hyperbilirubinemia.
3 Moderate-Hospitalized Patient has elevations in serum aminotransferase or alkaline phosphatase levels and total bilirubin is ≥ 2.5 
mg/dL or INR >= 1.5 and the patient is hospitalized (or a pre-existing hospitalization is prolonged) because of 
the drug-induced liver injury.
4 Severe Patient has elevations in serum aminotransferase or alkaline phosphatase levels and total bilirubin is ≥ 2.5 
mg/dL and there is at least one of the following:
• signs of hepatic decompensation (INR ≥ 1.5, ascites, or encephalopathy), or
• other organ failure believed to be associated with drug-induced liver injury event.
5 Fatal Patient dies or undergoes liver transplantation for drug-induced liver injury
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Table 2
Characteristics of INH Liver Injury Patients (n = 60)
Age in yrs., median (min., max.) 49 (4, 68)
Gender 42 women (70%)
Body Mass Index, kg/m2, mean (S.D.) 27.1 (5.5)
Race (self-report)
 White 34 (57%)
 Black/African American 13 (22%)
 Other* 13 (22%)
Ethnicity = Latino 15 (25%)
Indication for INH use
 Latent TB 56 (97%)
 Exposure to TB infected person 1 (2%)
 Active TB 1 (2%)
Concurrent alcohol use^ 22 (37%)
Concurrent liver disease
 Hepatitis C, chronic 7 (12%)
 Hepatitis B 0 (0%)
 Non-alcoholic fatty liver disease 0 (0%)
 Cirrhosis 0 (0%)
Latencies, mean days (S.D.)
 INH start to symptoms 85.7 (56.1)
 INH start to DILI onset|| 103.4 (59.5)
Signs and symptoms
 Jaundice 42 (70%)
 Nausea 32 (53%)
 Fever 9 (15%)
 Abdominal pain 27 (45%)
 Rash 8 (13%)
 Pruritus 17 (18%)
DILIN Causality scores
 1: Definite 29 (48%)
 2: Highly likely 23 (38%)
 3: Probable (single agent cases) 8 (13%)
Peak liver biochemistries (mean, std.dev.)
 ALT (IU/L) 1384 (864)
 AST (IU/L) 1467 (1137)
 AP (IU/L) 279 (159)
 Bilirubin (mg/dL) 12 (11.6)
INR 2 (4.3)
*
Pacific islander, Asia subcontinent, East Asia, unstated/unknown
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^At least one alcohol beverage in last 12 months
||ALT >5x ULN or AP >2x ULN on two consecutive tests
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